(Q54645696)

2 June 2018

title

Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials. (English)

1 reference

2 June 2018

main subject

phase I clinical trial

0 references

author name string

Stephane Ederhy

1

1 reference

2 June 2018

Christophe Massard

2

1 reference

2 June 2018

Ghislaine Dufaitre

3

1 reference

2 June 2018

Ratio Balheda

4

1 reference

2 June 2018

Catherine Meuleman

5

1 reference

2 June 2018

Carlos Gomez Rocca

6

1 reference

2 June 2018

Hassane Izzedine

7

1 reference

2 June 2018

Ariel Cohen

8

1 reference

2 June 2018

Jean-Charles Soria

9

1 reference

2 June 2018

publication date

6 October 2010

1 reference

2 June 2018

Investigational New Drugs

published in

1 reference

2 June 2018

volume

30

1 reference

2 June 2018

issue

2

1 reference

2 June 2018

page(s)

611-615

1 reference

2 June 2018

https://scigraph.springernature.com/pub.10.1007/s10637-010-9546-8

exact match

0 references

cites work

VEGF-targeted therapy: mechanisms of anti-tumour activity.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9546-8

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9546-8

Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9546-8

Vascular complications of selected cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9546-8

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9546-8

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9546-8

Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9546-8

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9546-8

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9546-8

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9546-8

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9546-8

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9546-8

Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9546-8

Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9546-8

Tumour vascular disrupting agents: combating treatment resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9546-8

Disrupting tumour blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9546-8

Vascular disrupting agents in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9546-8

Tyrosine kinases as targets for cancer therapy

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20924643

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-010-9546-8

1 reference

2 June 2018

PubMed ID

20924643

1 reference

2 June 2018